Article citationsMore>>

Yamaguchi, H., Akitaya, T., Yu, T., Kidachi, Y., Kamiie, K., Noshita, T., Umetsu, H. and Ryoyama, K. (2011) Homology modeling and structural analysis of 11β-hydroxysteroid dehydrogenase type 2. European Journal of Medicinal Chemistry, 46, 1325-1330. doi:10.1016/j.ejmech.2011.01.054

has been cited by the following article:

• TITLE: Homology modeling and structural analysis of human γ-glutamylcysteine ligase catalytic subunit for antitumor drug development

  AUTHORS: Hideaki Yamaguchi, Tatsuo Akitaya, Yumi Kidachi, Katsuyoshi Kamiie, Hironori Umetsu

  KEYWORDS: Antitumor Drug; GCLC; MOE

  JOURNAL NAME: Journal of Biophysical Chemistry, Vol.3 No.3, August 28, 2012

  ABSTRACT: Homology modeling and structural analysis of human glutamate cysteine ligase catalytic subunit (hGCLC) were performed with a software package the Molecular Operating Environment. A yeast GCLC (yGCLC; PDB code: 3LVV) was selected as a template for the 3D structure modeling of hGCLC. The modeled hGCLC showed significant 3D similarities at the ligand biding site (LBS) to the yGCLC structure. The contact energy profiles of the hGCLC model were in good agreement with those of the yGCLC structure. Ramachandran plots revealed that only 1.4% of the amino acid residues were in the disfavored region for hGCLC. The molecular electrostatic potential (MEP) map of the hGCLC model exhibited that the model was slightly different from the yGCLC model electrostatically at the LBS. Further, docking simulations revealed the similarity of the ligand-receptor bound location between the hGCLC and yGCLC models. The different binding orientations between the glutathione (GSH)-hGCLC and GSH-yGCLC complexes reflected the different MEP maps at the LBSs between the hGCLC and yGCLC models. These results indicate that the hGCLC model was successfully modeled and analyzed. To the best of our knowledge, this is the first report of a hGCLC model with detailed analyses, and our data verify that the model can be utilized for application to target hGCLC for the development of anticancer drugs.